Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 25 26 27 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
iOnctura–VI Partners: investment, 202001 financing round Series A totalling €15m incl new + co-lead investor VI Partners 2020-01-23
HepaRegenix–Boehringer: investment, 202001 financing round Series B totalling €11m incl existing investor BIVF 2020-01-21
HepaRegenix–Germany (govt): investment, 202001 financing round Series B totalling €11m incl existing investor Coparion 2020-01-21
HepaRegenix–High-Tech Gründerfonds: investment, 202001 financing round Series B totalling €11m incl existing investor HTGF 2020-01-21
HepaRegenix–Life Science-Stiftung: investment, 202001 financing round Series B totalling €11m incl existing investor Ascenion 2020-01-21
HepaRegenix–Novo Group: investment, 202001 financing round Series B totalling €11m incl existing investor Novo Seeds 2020-01-21
HepaRegenix–SEVERAL: investment, 202001 financing round Series B €11m with BIVF + Novo Holdings + HTGF + Coparion + Ascenion 2020-01-21
BioNTech–Covington & Burling: legal services, 202001 supply service legal counsel with regard to merger acquisition of Neon Therapeutics 2020-01-16
Neon Therapeutics–BioNTech: investment, 202001–202005 acquisition merger $67m by BioNTech in all-stock transaction with 0.063 ADSs/share = $2.18/share 2020-01-16
Neon Therapeutics–Goodwin Procter: legal services, 202001 supply service legal counsel with regard to merger acquisition by BioNTech 2020-01-16
Neon Therapeutics–Ondra Partners: financial services, 202001 supply service excl financial advisor with regard to merger acquisition by BioNTech 2020-01-16
QLi5 Therapeutics–Max Planck: investment, 202001 founding as joint venture of Qurient Co Ltd + MPG + LDC + Robert Huber 2020-01-16
QLi5 Therapeutics–PERSON: investment, 202001 founding as joint venture of Qurient Co Ltd + MPG + LDC + Robert Huber 2020-01-16
QLi5 Therapeutics–Qurient: investment, 202001 founding as joint venture of Qurient Co Ltd + MPG + LDC + Robert Huber 2020-01-16
QLi5 Therapeutics–SEVERAL: investment, 202001 founding as joint venture of Qurient Co Ltd + MPG + LDC + Robert Huber 2020-01-16
Biograil–High-Tech Gründerfonds: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl lead investor HTGF 2020-01-15
Biograil–SEVERAL: investment, 202001 seed financing round €3m (potentially up to €5m) led by HTGF 2020-01-15
Danaher–Sophia Genetics: genomic technologies, 202001– collab ww expansion IDT NGS enrichment products with Sophia Genetics DDM for clinical research 2020-01-15
Lunaphore–Alpana Ventures: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Alpana Ventures 2020-01-15
Lunaphore–Occident: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Occident 2020-01-15
Lunaphore–PHC: investment, 202001 financing round Series C totalling CHF23m incl new + lead investor PHC Holdings Corp 2020-01-15
Lunaphore–Redalpine: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Redalpine Venture Partners 2020-01-15
Lunaphore–SEVERAL: investment, 202001 financing round Series C CHF23m led by PHC Holdings Corp 2020-01-15
Temedica–Gruner + Jahr: investment, 202001 financing round Series B totalling €17m incl existing + co-investor G+J Digital Ventures 2020-01-14
Temedica–MIG Fonds: investment, 202001 financing round Series B totalling €17m incl co-lead investor MIG Funds 2020-01-14
Temedica–PERSON: investment, 202001 financing round Series B totalling €17m incl existing + co-investor Bernd Wendeln 2020-01-14
Temedica–Salvia: investment, 202001 financing round Series B totalling €17m incl co-lead investor Salvia 2020-01-14
Temedica–SEVERAL: investment, 202001 financing round Series B €17m led by MIG Funds + Santo VC + Salvia 2020-01-14
Temedica–Strüngmann Group: investment, 202001 financing round Series B totalling €17m incl co-lead investor Santo Venture Capital 2020-01-14
Amgen–Qiagen: molecular companion diagnostics, 202002– collab developm KRAS G12C CDx for AMG 510 in NSCLC 2020-01-13
Andrew Alliance–Waters: investment, 202001 acquisition by existent investor Waters 2020-01-13
Daiichi Sankyo–ERS Genomics: CRISPR technology, 202001– license ww excl €na for internal RnD 2020-01-13
Illumina–Roche: genomic cancer testing, 202001–201412 collab €na strategic alliance non-excl for NGS-based cancer testing for IVD + CDx 2020-01-13
Incyte–MorphoSys: tafasitamab, 202001– collab + ww excl license incl US co-commercialisation $750m upfront + $1.1b milestones 2020-01-13
MorphoSys–Incyte: investment, 202001 equity investment $150m in new ADSs at premium to share price as part of tafasitamab collab/license agreement 2020-01-13
NBE Therapeutics–Boehringer: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor BIVF 2020-01-10
NBE Therapeutics–OTHER: investment, 202001 financing round Series C USD22m incl all existing private shareholders 2020-01-10
NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group 2020-01-10
NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C $22m led by existing investors BIVF + PPF Group wih all private investors 2020-01-10
Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi 2020-01-09
Bayer–Evotec: drug discovery services, 201001–202412 collab expansion women’s health €16.5m upfront + research cost + milestones >€330m drugs for PCOS 2020-01-09
Bayer–Exscientia: AI-based drug discovery, 202001–202312 collab identification lead structures for drugs to treat cardiovascular diseases + cancers 2020-01-09
Cunesoft–Phlexglobal: investment, 202001 acquisition of Cunesoft GmbH by Phlexglobal 2020-01-08
Eyevensys–Bellevue: investment, 202001 financing round Series B totalling $30m incl new + co-investor Pureos Bioventures 2020-01-08
Eyevensys–Boehringer: investment, 202001 financing round Series B totalling $30m incl existing + lead investor Boehringer Ingelheim Venture Fund 2020-01-08
Eyevensys–SEVERAL: investment, 202001 financing round Series B $30m led by Boehringer Ingelheim Venture Fund 2020-01-08
Immunic–Daiichi Sankyo: IMU-856, 202001– license excl ww €na option exercised by Immunic AG 2020-01-08
Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve 2020-01-08
Wellington Partners–MC Services: public relations, 202001 service existent by MC Services 2020-01-08
Boehringer–PhoreMost: drug discovery services, 202001– collab €na multi-project target discovery using Siteseeker platform 2020-01-07
CytomX Therapeutics–Genedata: bioinformatics, 202001– supply license for Genedata Bioprocess platform to CytomX Therapeutics 2020-01-07
MiNA Therapeutics–Trophic Communications: public relations, 202001 service existent by Trophic Communications 2020-01-07
VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors 2020-01-07
VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative 2020-01-07
VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings 2020-01-07
VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed 2020-01-07
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. 2020-01-07
VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors 2020-01-07
VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures 2020-01-07
VectivBio–WPP: public relations, 202001 service existent by Glover Park Group 2020-01-07
Velabs Therapeutics–Alytas Therapeutics: therapeutic antibodies, 202001– license excl for developm + commercialisation of Abs in field of senescence 2020-01-07
Bruker–Adeptrix: MS-based immunoassays, 202101– collab developm BAMS assays on Bruker MALDI-MS systems 2020-01-06
Bayer–Daré Bioscience: contraceptives, 202001– license excl for US for hormone-free monthly vagial contraceptive 2020-01-01
Innerspace–High-Tech Gründerfonds: investment, 2020 seed financing round incl investor HTGF 2020-01-01
Innerspace–MAD Ventures: investment, 2020 seed financing round incl investor MAD Ventures GmbH 2020-01-01
Innerspace–SEVERAL: investment, 2020 seed financing round with MAD Ventures + HTGF 2020-01-01
KLIFO–Gilde Investment: investment, 202105 acquisition of majority share in KLFIO A/S by Gilde Healthcare 2020-01-01
MediServ–KLIFO: investment, 2020 acquisition of MediServ by KLIFO A/S 2020-01-01
Sartorius–Nvidia: AI-based drug discovery + manufacturing, 2020– collab integration of Nvidia technology in Sartorius instruments + for simulations 2020-01-01
Tecan–Labforward: laboratory software, 2020– collab integration of Tecan detection devices with Labfolder LIMS 2020-01-01
TherVacB project–EU (govt): grant, 202001–202412 Horizon 2020 grant €10.4m for development of therapeutic Hepatitis B vaccine 2020-01-01
Vaderis Therapeutics–Medicxi: investment, 2020 Series A financing CHF18m from Medicxi 2020-01-01
Aeovian Pharmaceuticals–Evotec: investment, 201912 investment existent Evotec owns 5.83% of voting rights 2019-12-31
Autobahn Labs–Evotec: investment, 201912 investment existent Evotec owns 33.33% of voting rights 2019-12-31
Blacksmith Medicines–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights 2019-12-31
Breakpoint Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 48.6% of voting rights 2019-12-31
Carrick Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 4.29% of voting rights 2019-12-31
Celmatix–Evotec: investment, 201912 investment existent Evotec owns 25.02% of voting rights 2019-12-31
Eternygen–Evotec: investment, 201912 investment existent Evotec owns 24.97% of voting rights 2019-12-31
Exscientia–Evotec: investment, 201912 investment existent Evotec owns 23.21% of voting rights 2019-12-31
Fibrocor Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 16% of voting rights of Fibrocor LLP 2019-12-31
Forge Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights 2019-12-31
FSHD Unlimited Coop–Evotec: investment, 201912 investment existent Evotec owns 21.12% of voting rights 2019-12-31
Immunitas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 6.44% of voting rights 2019-12-31
Topas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 28.44% of voting rights 2019-12-31
Vico Therapeutics–Bellevue: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Pureos Bioventures 2019-12-31
Vico Therapeutics–Eurazeo: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Idinvest Partners 2019-12-31
Provecs–NONE: investment, 201912–202001 bankruptcy AG Hamburg 67g IN 290/19 insolvency + dissolution Provecs Medical GmbH 2019-12-30
Roche–Sarepta: delandistrogene moxeparvovec-rokl, 201912– license excl ww outside US $750m cash + $400m equity upfront + $1.7b milestones for SRP-9001 2019-12-23
Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc 2019-12-20
Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors 2019-12-20
Nagi Bioscience–NEST Pension Fund: investment, 201912 seed financing round totalling CHF1.8m incl investor NEST Pension Fund 2019-12-20
Nagi Bioscience–OTHER: investment, 201912 seed financing round totalling CHF1.8m incl private investors from CH + US 2019-12-20
Nagi Bioscience–SEVERAL: investment, 201912 seed financing round CHF1.8m with investiere + ZKB + NEST Pension Fund + private investors from CH + US 2019-12-20
Nagi Bioscience–Verve Capital Partners: investment, 201912 seed financing round totalling CHF1.8m incl investor investiere 2019-12-20
Nagi Bioscience–Zürcher Kantonalbank: investment, 201912 seed financing round totalling CHF1.8m incl investor ZKB 2019-12-20
CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance 2019-12-19
Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies 2019-12-19
Kinnate Biopharma–Nextech: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd 2019-12-19
Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman 2019-12-19
next pagenext page 1 2 3 ... 25 26 27 ... 33 34 35  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top